Alzamend Neuro Inc. (ALZN)
Drugs • Health Care
July 22, 2026 Alzamend Neuro Inc. Reports 2026 Annual Results: A Year of Progress Amid Financial Challenges Alzamend Neuro Inc. reported its 2026 annual results, showing progress in clinical trials for AL001 and ALZN002 amidst financial struggles, including a net loss of $8.8 million. The company faces challenges in securing funding and legal issues while striving to develop innovative therapies for neurological disorders.
April 07, 2026 Alzamend Neuro Reports Positive Pharmacodynamic Data from Phase II Clinical Trial of AL001 Alzamend Neuro reported positive results from its Phase II trial of AL001, showing a distinct neurochemical footprint compared to lithium carbonate. These findings suggest AL001 may offer a safer and more effective treatment for neurological disorders.
March 26, 2026 Alzamend Neuro Reports Promising Phase II Trial Data for AL001 Alzamend Neuro has reported significant results from its Phase II trial of AL001, showcasing bioequivalence to lithium carbonate and improved brain delivery. This breakthrough could revolutionize treatment for Alzheimer's, bipolar disorder, and other neuropsychiatric conditions.
March 16, 2026 Alzamend Neuro Launches Phase II Trial for AL001 in Bipolar Disorder Alzamend Neuro has launched a Phase II clinical trial for AL001, a new lithium-based therapy for bipolar disorder type 1, in partnership with Massachusetts General Hospital. This innovative treatment aims to improve efficacy and reduce side effects for patients suffering from this mental health condition.
July 22, 2025 Alzamend Neuro Inc.: 2025 Annual Report Insights Alzamend Neuro's 2025 Annual Report highlights its commitment to developing therapies for Alzheimer's and other neurological disorders. Despite no revenue, the company has reduced operational costs while advancing clinical trials for its lead product candidate, AL001, and faces challenges in securing additional funding.
March 01, 2025 SWOT Analysis of Alzamend Neuro Inc. in 2025 This article provides a detailed SWOT analysis of Alzamend Neuro Inc. in 2025, examining its strengths in neurotherapeutics, weaknesses in financial stability, opportunities in the growing mental health market, and threats from competition. The company faces critical challenges and must navigate complex regulatory landscapes for successful product development.
February 19, 2025 Alzamend Neuro Inc. Advances Alzheimer’s Research with Innovative Head Coil Development Alzamend Neuro has developed a novel head coil for advanced brain imaging, set to enhance lithium treatment in Alzheimer's and other psychiatric disorders. This technology promises improved understanding and application of lithium therapies, potentially benefiting patients significantly.
July 30, 2024 Alzamend Neuro Inc. Releases 2024 Annual Report: A Year of Challenges and Progress Alzamend Neuro's 2024 Annual Report showcases financial improvements amid challenges, with a notable decrease in losses and advancements in clinical trials for mental health therapies. The company aims to enhance its financial position through strategic fundraising and product development.
March 25, 2024 Alzamend Neuro Inc. Reports Q3 2024 Results: A Struggle Amid Clinical Progress Alzamend Neuro Inc. reported a reduced net loss of $2.66 million in Q3 2024, while facing stagnant revenue and significant liabilities. Despite financial struggles, the company made progress in clinical trials for its lead candidate, AL001, raising hopes for future success.